HeartBeam, Inc. (BEAT) - 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring on July 11, 2025, specifically the Company's Annual Meeting of Stockholders held virtually. HeartBeam, Inc. is a Delaware corporation with its principal executive offices in Santa Clara, CA. The Company is classified as an emerging growth company.
Key Financial Metrics
This filing is a corporate governance report and does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The filing text does not provide a clear value for any financial statement items.
Material Changes and Voting Results
The filing details the outcomes of three proposals voted upon at the Annual Meeting. As of the record date (May 12, 2025), 33,809,707 shares were outstanding, with approximately 55.32% represented at the meeting.
- Director Elections: All nine nominees were elected to one-year terms. Notable voting dissent included:
- Marga Ortigas-Wedekind: 1,878,916 votes against (approx. 26.5% of votes cast).
- Mark Strome: 1,531,719 votes against (approx. 21.6% of votes cast).
- Other directors received less than 5% of votes against.
- Independent Auditor Ratification: The proposal to ratify CBIZ CPAs P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was approved with 18,388,997 votes for and 55,859 votes against.
- Equity Plan Amendment: The proposal to amend the 2022 Equity Incentive Plan to increase authorized shares from 8,900,000 to 11,900,000 was approved. The vote was 4,375,827 for and 2,717,474 against.
Guidance, Outlook, and Risks
This filing contains no management commentary regarding future guidance, outlook, risks, contingencies, or unusual items. The document is strictly a report of the stockholder vote results and the submission of the amended equity plan as an exhibit.
Investor Verification Checklist
- Verify the impact of the significant "against" votes for directors Marga Ortigas-Wedekind and Mark Strome on future board composition or governance strategy.
- Review the terms of the Third Amendment to the 2022 Equity Incentive Plan (Exhibit 10.1) to understand the dilution implications of increasing authorized shares by 3 million.
- Confirm the Company's status as an emerging growth company and any associated reporting exemptions.
- Check subsequent filings (e.g., 10-K or 10-Q) for the actual financial performance data absent from this 8-K.